This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
KPI Therapeutics, Inc.
Drug Names(s): dalazatide analogue, ShK-186
Description: KPI-150 is a related peptide of ShK that inhibits the Kv1.3 channel on effector memory T cells, which are the subset of T cells that are found at the sites of inflammation in a variety of different autoimmune diseases. Targeting TEM lymphocytes without affecting naïve and central memory lymphocytes, has the potential to effectively treat TEM-mediated diseases without inducing generalized immunosuppression.
Additional information available to subscribers only: